Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 12.08.2022 16:18
Latest

3.64 NOK

Change

0.02

Change (%)

0.55

HBC 1
LATEST REPORT

Quarterly Report Q3

Download our latest report, or view all quarterly and yearly reports in the archives.

16:9
NEXT UP

Financial calendar

Half-yearly Report
26.08.2022

Quarterly Report Q1
06.05.2022

Quarterly Report Q3
11.11.2022

Quarterly Report Q4
10.02.2023

Investor presentation

Download our latest investor presentation in PDF-format for a even deeper insight into our current ongoing business and future potential.

Download presentation

Contact investor relations

James portrett
James Berger
Chief Commercial Officer
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford portrett
Dr. Crawford Currie
Head of Medical R&D
+44 7968 195497 cc@hofsethbiocare.no